Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Periodic limb movements in sleep elevate SBP in patients with OSA

07 Aug 2020

An association exists between periodic limb movements during sleep (PLMS) and an increase in systolic blood pressure (SBP) regardless of apnoea–hypopnea index (AHI) in patients with obstructive sleep apnoea (OSA), independent of clinical and sociodemographic confounders, a recent study has found.

“OSA and PLMS are known to induce acute BP swings during sleep,” the investigators noted.

Univariate analysis revealed an increased SBP equal to 4.70 mm Hg (p<0.001) in patients with significant PLMS compared to those without. This increase persisted even after implementing a multivariable regression model (2.64 mm Hg; p=0.044). Of note, there was no significant risk observed for diastolic (D)BP and pulse pressure.

“A PLMS phenotype may carry an increased risk for cardiovascular disease in OSA patients,” the investigators said.

This cross-sectional analysis sought to address the independent effect of PLMS on BP in an OSA patient cohort. A total of 1,487 patients (mean age, 52.5 years; mean body mass index [BMI], 30.5 kg/m2; 1,110 males; no previous hypertension diagnosis or treatment) with significant OSA, defined as AHI ≥10, were recruited from the European Sleep Apnoea Cohort. They underwent overnight polysomnography.

The investigators stratified the participants into two groups: those with significant PLMS (PLMS index >25 events/hour of sleep) and those without (PLMS index <25 events/hour of sleep. SBP, DBP, and PP were variables of interest. A multivariate regression linear model was fitted for each of these to examine the association between PLMS and outcome adjusting for sociodemographic and clinical covariates (eg, age, gender, BMI, AHI, Epworth Sleepiness Scale, diabetes, smoking, and sleep efficiency).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.